ViewRay slides after slashing annual revenue outlook

Viewray

13/04/2023 15:04

(Updates)
    ** Radiation therapy system maker ViewRay Inc's  VRAY.O 
shares slide ~35%, hitting near 3-yr low at $1.94
    ** Company cuts fiscal 2023 revenue forecast range to about
zero to 15% growth, from previous outlook of 25% to 40% growth 
    ** VRAY says its board has retained Goldman Sachs and Co LLC
as financial adviser for evaluation of strategic alternatives
    ** Company updates 2023 adj EBITDA outlook range to loss of
$75 mln to $85 mln vs previous forecast of loss of $70 mln to
$80 mln
    ** Co's stock down 56.6% YTD, including session's fall  

 (Reporting by Amna Karimi and Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))